Loading clinical trials...
Loading clinical trials...
A Phase 1/2, Open-Label, Multi-Center Trial to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CLN-081 in Patients With Locally-Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Previously Received Platinum-Based Systemic Chemotherapy
Conditions
Interventions
CLN-081
Locations
64
United States
Pacific Cancer Medical Center, Inc
Anaheim, California, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
City of Hope at Irvine Lennar
Irvine, California, United States
Pacific Shores Medical Group
Long Beach, California, United States
AdventHealth
Orlando, Florida, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
October 31, 2019
Primary Completion Date
January 31, 2026
Completion Date
March 31, 2026
Last Updated
March 13, 2025
NCT05671510
NCT03340506
NCT07485114
NCT06066138
NCT05098132
NCT04977453
Lead Sponsor
Cullinan Therapeutics Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions